Cell & Gene Therapy Expertise

The science is stunningly complex, and the regulatory terrain is constantly evolving. Having supported 60 cell and gene therapy trials in the past five years spanning oncology, hematology, metabolic disorders, and more, we know what it takes to succeed.

prcom_Asset 1ARROW

Supporting the evolving science of cell and gene therapy

Even measured against the vast scientific mystery that defines the biotech industry, cell and gene therapy poses extraordinary challenges. To achieve operational excellence in these trials, you must understand — and overcome — obstacles ranging from start-up regulations and site selection to patient recruitment and retention. And given the limited data on the long-term effects of these therapies, participants in cell and gene therapy trials may be monitored for a long-term follow-up period, which may be as long as 15 years.

For projects of this scale, you need a partner that can deliver from start to finish. That’s where Premier Research comes in.

We combine deep therapeutic expertise in oncology, rare disease, and pediatric research with other key areas, such as collaborative monitoring processes and technology. Together these allow us to deliver high-quality outcomes and an unwavering commitment to developers of next-generation therapies that makes us truly Built for Biotech℠.

Why choose Premier?
  • 60 cell and gene therapy studies conducted in the past five years
  • Significant experience in viral vectors
  • Significant experience in both oncology and non-oncology

Navigating global regulatory frameworks

Understanding how cell and gene therapy products are regulated — and how to navigate regional or national regulatory differences — can help you develop an efficient product development plan to bring your treatment to patients in need.

Managing long-term follow-up studies

To understand and mitigate the risk of delayed adverse events, participants in gene and cell therapy trials may be monitored for a long-term follow-up period. Learn what’s needed and how to determine if your product requires LTFU studies.

Featured Resources

Premier Insight

Premier Insight

#272: Delivering the Global Expertise Required to Coordinate a Pediatric Gene Therapy Trial

White Paper

White Paper

Operationalizing Gene Therapy Trials

Premier Insight

Premier Insight

#274: Site Selection, Manufacturing, & Long-Term Follow-Up in a Transition Phase 1/2 Gene Therapy Trial

Cell & Gene Therapy Expert

Jessica Merryfield

Jessica Merryfield

Executive Director, Cell & Gene Therapy
Kenneth Ndugga-Kabuye, MD, FACMG

Kenneth Ndugga-Kabuye, MD, FACMG

Vice President, Cell & Gene Therapy

Connect with us

Ready to get started? So are we. Drop us a line to learn more about how we can help.